Friday, October 6, 2017
=uniQure (QURE) : AMT-130 received Orphan Drug Designation (ODD) by FDA.
uniQure announces that AMT-130 received Orphan Drug Designation (ODD) by FDA.
There are currently no approved medical treatments aimed at addressing the underlying cause of Huntington's disease, and AMT-130 has the potential to play a role in this area of high unmet medical need.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment